News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Neoadjuvant nivolumab with or without ipilimumab in early stage TNBC
Photo of Iris Nederlof from oncologie.nu
Sep 21, 2024, 09:03

Neoadjuvant nivolumab with or without ipilimumab in early stage TNBC

Top Biomedical Science shared a post on X, about recent paper published in Nature Medicine:

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Authors: Iris Nederlof, Olga I. Isaeva, Manon de Graaf, Robbert C. A. M. Gielen, Noor A. M. Bakker, Adrianne L. Rolfes, Hannah Garner, Bram Boeckx, Joleen J. H. Traets, Ingrid A. M. Mandjes, Michiel de Maaker, Thomas van Brussel, Maksim Chelushkin, Elisa Champanhet, Marta Lopez-Yurda, Koen van de Vijver, José G. van den Berg, Ingrid Hofland, Natasja Klioueva, Ritse M. Mann, Claudette E. Loo, Frederieke H. van Duijnhoven, Victoria Skinner, Sylvia Luykx, Emile Kerver, Ekaterina Kalashnikova, Marloes G. J. van Dongen, Gabe S. Sonke, Sabine C. Linn, Christian U. Blank, Karin E. de Visser, Roberto Salgado, Lodewyk F. A. Wessels, Caroline A. Drukker, Ton N. Schumacher, Hugo M. Horlings, Diether Lambrechts, Marleen Kok.

Top Biomedical Science

”Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial at Nature Medicine.”

Source: Top Biomedical Science/X

Adrianne L. Rolfes Bram Boeckx Breast Cancer cancer cancer trial Caroline A. Drukker Christian U. Blank Claudette E. Loo Diether Lambrechts Ekaterina Kalashnikova Elisa Champanhet Emile Kerver Frederieke H. van Duijnhoven Gabe S. Sonke Hannah Garner Hugo M. Horlings Ingrid A. M. Mandjes Ingrid Hofland ipilimumab Iris Nederlof Joleen J. H. Traets José G. van den Berg Karin E. de Visser Koen van de Vijver Lodewyk F.A. Wessels Maksim Chelushkin Manon de Graaf Marleen Kok Marloes G. J. van Dongen Marta Lopez-Yurda Michiel de Maaker Natasja Klioueva Nature Medicine nivolumab Noor A. M. Bakker Olga I. Isaeva OncoDaily Oncology Ritse M. Mann Robbert C. A. M. Gielen Roberto Salgado Sabine C. Linn Sylvia Luykx Thomas van Brussel Ton N. Schumacher Top Biomedical Science Victoria Skinner
Special Coverage
Blog
Jan 20, 2025, 04:32
Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma
Blog
Jan 20, 2025, 04:29
Katsuaki Maehara: Lung EGFR mutations catalog
Opinion
Jan 20, 2025, 04:25
Elisabetta Bonzano: The identification and validation of patient-specific vulnerabilities
Blog
Jan 20, 2025, 04:21
Robin Zon: Behind every diagnosis, test, approval/ disapproval and outcome is a patient and their family
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL
Science
Jan 20, 2025, 02:16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Blog
Jan 20, 2025, 02:14
Akriti Jain: Grateful to present at Cleveland Clinic ASH review
Career
Jan 19, 2025, 23:12
Kimryn Rathmell Steps Down as NCI Director, Concluding a Pivotal Leadership Era